According to a report by IMS Health, the pharmaceutical market was reported at Rs 6370 crores for the month of May 2013, with a growth of 6.8 per cent.
| Source: IMS Health TSA, May 2013. |
Kumar Hinduja, Sr Director, Strategy Planning, Business Development, Pharma & Payer Solutions, IMS Health, said, “ We have seen a slight dip in the market for the month of May 2013 (compared to the previous month), as well as a subdued growth (6.8 per cent) as compared to the same month, last year. Though traditionally the market in May is relatively weak (as compared to April) on account of summer vacations and the prevalent heat conditions, we believe that some market factors have further dampened sales uptake in May, this year. One factor was the apprehension in the trade on the imminent implementation of DPCO 2013 and its implication on their business, including recall / re-labelling of formulations which would undergo price revisions. Uncertainty around this appears to have prompted majority of dealers to maintain lower inventory levels of drugs during the month – both at retail as well as stockist levels. For the same reasons, trade schemes (which generally induce higher uptake of goods) were almost absent in the market, this May.”
For the period MAT May 2013, the pharma market was reported at Rs 74,117 crore, with a growth of 10 per cent, over the same period last year.
Summary highlights for the May 2013 reports are as follows:
Leading corporations performance
The Top-10 corporations for the month of May 2013 were as follows:
| May’13 Ranking | Corporations | Month | 12 Months to date | |||||
| Mat | Mon | Val Crs. | MS % | Val Gr% | Val Crs. | MS % | Val Gr% | |
| TOTAL MARKET | 6,370 | 100.0 | 6.8 | 74,117 | 100.0 | 10.0 | ||
| 1 | 1 | ABBOTT | 441 | 6.9 | 4.3 | 5,172 | 7.0 | 6.2 |
| 2 | 2 | CIPLA | 302 | 4.7 | 4.2 | 3,623 | 4.9 | 7.4 |
| 3 | 3 | SUN | 297 | 4.7 | 15.4 | 3,277 | 4.4 | 15.8 |
| 5 | 4 | RANBAXY | 246 | 3.9 | 0.5 | 3,028 | 4.1 | 2.7 |
| 6 | 5 | ZYDUS CADILA | 245 | 3.8 | 1.3 | 2,930 | 4.0 | 7.6 |
| 4 | 6 | GLAXOSMITHKLINE | 239 | 3.8 | -4.0 | 3,032 | 4.1 | 6.4 |
| 7 | 7 | ALKEM | 222 | 3.5 | 13.7 | 2,484 | 3.4 | 12.7 |
| 8 | 8 | MANKIND | 203 | 3.2 | -2.7 | 2,477 | 3.3 | 10.4 |
| 9 | 9 | PFIZER | 199 | 3.1 | 2.8 | 2,376 | 3.2 | 7.6 |
| 10 | 10 | SANOFI | 186 | 2.9 | 9.3 | 2,131 | 2.9 | 14.9 |
For the month of May 2013, Sun, Alkem and Sanofi were the fastest growing corporations among the Top 10 companies. Among the Top 20 companies, USV was the fastest growing company (21.1 per cent) for May 2013, as well as for the period MAT May 2013 (21.9 per cent).
For the month, local companies are growing relatively stronger at 7.4 per cent, while MNCs grew at 5.3 per cent. While the Top 10 companies with a combined share of 40.5 per cent grew at 4.3 per cent for the month, it is the next set of companies (Rank 11 – 20 & Rank 21 – 100) that show higher growth.
| Source: IMS Health TSA, May 2013. |
Leading therapy performance:
Anti-diabetics was the fastest growing therapy for the month of May 2013 (18.0 per cent), followed by dermatology (13.3 per cent) and cardiac drugs (11.2 per cent).
Chronic therapies continue to show relatively stronger growths for the month underlining the growing penetration of these disease conditions in the Indian population.
| May 2013 | ||||
| Therapy | Value in Rs Crore | Contribution % | Growth % | |
| Total Market | 6370 |
100.0 |
6.8 | |
| ACUTE | 4472 |
70.2 |
5.0 |
|
| CHRONIC | 1898 |
29.8 |
11.3 |
|
Source: IMS Health TSA, May 2013.
Leading brands performance
| May’ 13 Ranking | Corporations | Months | 12 Months to date | |||||
| Mat | Mon | Val Crs. | MS % | Val Gr% | Val Crs. | MS % | Val Gr% | |
| TOTAL MARKET | 6,370 | 100.0 | 6.8 | 74,117 | 100.0 | 10.0 | ||
| 3 | 1 | PHENSEDYL COUGH | 27.0 | 0.42 | 53.9 | 282.6 | 0.38 | -5.6 |
| 5 | 2 | HUMAN MIXTARD30/70 | 23.8 | 0.37 | 8.9 | 261.1 | 0.35 | 2.2 |
| 1 | 3 | AUGMENTIN | 22.9 | 0.36 | 1.8 | 294.2 | 0.40 | 8.5 |
| 4 | 4 | VOVERAN | 22.7 | 0.36 | 1.9 | 263.0 | 0.35 | 13.9 |
| 2 | 5 | COREX | 21.2 | 0.33 | 3.5 | 286.2 | 0.39 | 8.1 |
| 7 | 6 | LIV-52 | 19.2 | 0.30 | 13.7 | 219.3 | 0.30 | 29.9 |
| 6 | 7 | MONOCEF | 18.8 | 0.30 | -10.7 | 237.4 | 0.32 | 13.8 |
| 10 | 8 | DEXORANGE | 18.8 | 0.30 | 17.9 | 183.4 | 0.25 | 6.0 |
| 13 | 9 | GLYCOMET-GP | 17.0 | 0.27 | 85.9 | 170.8 | 0.23 | 48.7 |
| 8 | 10 | BETADINE | 16.9 | 0.26 | 9.5 | 200.1 | 0.27 | 12.9 |
Source: IMS Health TSA, May 2013
EP News Bureau – Mumbai